WebApr 3, 2024 · Despite these results, Cytokinetics drew out some positive signals of efficacy from a post hoc analysis of the data. After consulting with the FDA, the company decided to push through with a Phase III study of reldesemtiv, Robert Blum, president and CEO, Cytokinetics, told BioSpace in an email. WebApr 10, 2024 · SOUTH SAN FRANCISCO, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the 22 nd Annual Needham Virtual Healthcare Conference on Monday, April 17, 2024 at 10:00 …
Cytokinetics CEO: Why It
WebMay 7, 2024 · Cytokinetics, Incorporated (NASDAQ:CYTK) Q1 2024 Earnings Conference Call May 6, 2024 4:30 PM ET Company Participants Diane Weiser – Senior Vice … WebMar 31, 2024 · Cytokinetics Announces COURAGE-ALS Met Criteria for Futility at Second Interim Analysis. Cytokinetics to Host Conference Call and Webcast Today at 8:30 am Eastern Time. SOUTH SAN FRANCISCO, Calif., March 31, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Data Monitoring … on the vine sprouts
RTW Investments, LP, Ji Xing Pharmaceuticals and Cytokinetics …
WebCytokinetics. We are developing potential medicines to improve the healthspan of people with devastating cardiovascular and … WebMar 31, 2024 · The company in the coming months will assess measures needed for the development of its neuromuscular pipeline, Cytokinetics CEO Robert Blum said in a statement. ALS, also known as Lou Gehrig’s disease, breaks down nerve cells in the brain and spinal cord that make muscles work, leading to progressive paralysis and death. ... WebCytokinetics, Inc. is a publicly traded biopharmaceutical company based in South San Francisco, California, ... In January 2007, Cytokinetics named Robert I. Blum as president and CEO. Prior to this, Blum has been involved in the company since its founding, ... ios fastclick